Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective

J Control Release. 2021 Aug 10:336:71-88. doi: 10.1016/j.jconrel.2021.06.011. Epub 2021 Jun 10.

Abstract

There is a growing demand for effective treatments for ocular conditions that improve patient compliance and reduce side-effects. While methods such as implants and injections have proven effective, topical administration remains the method of choice for the delivery of therapeutics to the anterior segment of the eye. However, topical administration suffers from multiple drawbacks including low bioavailability of the target therapeutic, systemic toxicity, and the requirement for high therapeutic doses due to the effective clearance mechanisms that exist in the eye. Nanoparticles that have tunable mucoadhesion and/or mucopenetration offer outstanding potential to overcome the anatomical and physiological barriers present to improve ocular bioavailability, reduce toxicity, and increase ocular retention, among other benefits. The current review highlights recent advances in the field of developing nanocarriers with tunable mucoadhesion and mucopenetration for drug delivery to the eye.

Keywords: Mucoadhesion; Mucopenetration; Nanoparticle; Ocular drug delivery; Topical administration.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Ophthalmic
  • Administration, Topical
  • Drug Delivery Systems
  • Eye
  • Humans
  • Nanoparticles*
  • Pharmaceutical Preparations*

Substances

  • Pharmaceutical Preparations